open-label BE trials maintain blindness [Study Per­for­mance]

posted by kimhuang – China, 2023-10-14 11:19 (630 d 08:21 ago) – Posting: # 23752
Views: 5,937

How do open-label BE trials maintain blindness until the database is locked?
Holding a data review meeting before DBL to discuss whether PK parameters (such as Pre-dose concentration, Abnormal PK concentration profiles, λz estimation, %AUCextrap etc.) are included in the analysis set (without treatment assigment) will have risk of potential unblinding?


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,686 registered users;
50 visitors (0 registered, 50 guests [including 7 identified bots]).
Forum time: 19:41 CEST (Europe/Vienna)

In the field of observation,
chance favors only the mind that is prepared.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5